KALVKalVista Pharmaceuticals Inc
$27.00
$0.01
(0.04%)
Closed $27.00
$0.01
(0.04%)
After Hours
EarningsAug 13
Mkt Cap$1.44B
Vol4.27M
Fundamentals
Mkt Cap
$1.44B
Volume
-
52W High
$27.00
52W Low
$9.83
PE Ratio
-6.75
Avg. Volume
3.77M
EPS (Annual)
-$3.23
Rev/Employee
$267,698.18
Earnings
Aug 13
60
Bullish Sentiment
How do you feel about KALV?
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 211 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). These data highlight the significant unmet needs...
Business Wire
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...
Business Wire
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...
PR Newswire
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to receive...
PR Newswire
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High - Here's Why
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Still a Buy...
MarketBeat
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...
PR Newswire
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...
Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright
HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Friday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest KALV News
ViewKalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
Business Wire
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?
PR Newswire
Advertisement|Remove ads.